Inhibition of exercise-induced shortening of bleeding time by fish oil in familial hypercholesterolemia (type IIa).

Hansen, John‐Bjarne; Lyngmo, V.; Svensson, B.; Nordøy, Arne

doi:10.1161/01.atv.13.1.98

Cited by 23 publications

(10 citation statements)

References 36 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Nicotinic acid which may effectively reduce both TC and TG levels may have adverse effects on glucose metabolism and is often difficult to tolerate. It has previously been shown that the combination of omega-3 fatty acids and statins may effectively reduce both total cholesterol and triglycerides in patients with combined hyperlipidemia and familial hypercholesterolemia [8,36]. The present study has confirmed these observations and furthermore has shown that omega-3 fatty acids have an additive effect in lowering triglycerides, total cholesterol (borderline) and apoE when added to the statins.…”

Section: Discussionsupporting

confidence: 87%

Effects of Simvastatin and omega‐3 fatty acids on plasma lipoproteins and lipid peroxidation in patients with combined hyperlipidaemia

Nordøy¹,

Bønaa

Nilsen

et al. 1998

Journal of Internal Medicine

View full text Add to dashboard Cite

Abstract. Nordøy A, Bønaa KH, Nilsen H, Berge R, Hansen JB, Ingebretsen OC (University of Tromsø, Tromsø, Norway). Effects of Simvastatin and omega-3 fatty acids on plasma lipoproteins and lipid peroxidation in patients with combined hyperlipidemia. J Intern Med 1998; 243: 163-70.Objectives. Patients with combined hyperlipidemia are at increased risk for development of coronary heart disease. The purpose of this study was to evaluate the efficiency and the safety of treatment with Simvastatin and omega-3 fatty acids in patients with this lipid disorder. Design. A double-blind placebo controlled, randomized study evaluating the effects of Simvastatin separately and in combination with omega-3 fatty acids in 41 healthy patients with defined hyperlipidemia. After a 16 weeks dietary run-in period the patients were treated in periods of 5 weeks. Results.As expected Simvastatin (20 mg day Ϫ1 ) reduced serum total cholesterol, triacylglycerols, apolipoproteins B and E and increased HDL-cholesterol and apolipoprotein A 1 . Addition of omega-3 fatty acids (4 g day Ϫ1 ) further decreased serum triacylglycerols (P ϭ 0.007), total cholesterol (P ϭ 0.052) and apolipoprotein E (P ϭ 0.035). No significant changes attributable to supplementation of polyunsaturated fatty acids on the content of lipid peroxides in plasma and in the various lipoprotein fractions were observed. Conclusions. The combined treatment of Simvastatin and omega-3 fatty acids seems to be an efficient and safe alternative for patients with combined hyperlipidemia.

show abstract

Section: Discussionsupporting

confidence: 87%

Effects of Simvastatin and omega‐3 fatty acids on plasma lipoproteins and lipid peroxidation in patients with combined hyperlipidaemia

Nordøy¹,

Bønaa

Nilsen

et al. 1998

Journal of Internal Medicine

View full text Add to dashboard Cite

show abstract

“…19,26,27 Unfortunately, data on minor injuries were not available for our cohort to test this hypothesis. Furthermore, physical exercise of moderate and high intensity is associated with several immediate alterations in the hemostatic system, such as increased platelet reactivity, 28 shortened bleeding-time, 29 elevated plasma levels of factor VIII, 30 von Willebrand factor, 30,31 and fibrinogen, 32 increased plasma viscosity, 32 increased endogenous thrombin formation assessed by thrombin-antithrombin complex formation, 30 and transient increased fibrinolytic activity associated with increased plasma levels of tissue plasminogen activator 33 with subsequent inhibition of fibrinolytic activity monitored by prolongation of whole blood clot lysis time. These acute prothrombotic changes in the hemostatic system may contribute to the increased risk of acute coronary syndromes associated with physical exertion.…”

Section: © F E R R a T A S T O R T I F O U N D A T I O Nmentioning

confidence: 99%

Physical activity and risk of venous thromboembolism. The Tromso study

Borch¹,

Hansen-Krone²,

Brækkan³

et al. 2010

Haematologica

View full text Add to dashboard Cite

BackgroundPrevious studies have shown differences in the impact of regular physical exercise on the risk of venous thromboembolism. The inconsistent findings may have depended on differences in study design and specific population cohorts (men only, women only and elderly). We conducted a prospective, population-based cohort to investigate the impact of regular physical exercise on the risk of venous thromboembolism. Design and MethodsRisk factors, including self-reported moderate intensity physical exercise during leisure time, were recorded for 26,490 people aged 25-97 years old, who participated in a population health survey, the Tromsø study, in 1994-95. Incident venous thromboembolic events were registered during the follow-up until September 1, 2007. ResultsThere were 460 validated incident venous thromboembolic events (1.61 per 1000 person-years) during a median of 12.5 years of follow-up. Age, body mass index, the proportion of daily smokers, total cholesterol, and serum triglycerides decreased (P<0.001), whereas high density cholesterol increased (P<0.001) across categories of more physical exercise. Regular physical exercise of moderate to high intensity during leisure time did not significantly affect the risk of venous thromboembolism in the general population. However, compared to inactivity, high amounts of physical exercise (≥3 hours/week) tended to increase the risk of provoked venous thromboembolism (multivariable hazard ratio, 1.30; 95% confidence interval, 0.84-2.0), and total venous thromboembolism in the elderly (multivariable hazard ratio, 1.33; 95% confidence interval, 0.80-2.21) and in the obese (multivariable hazard ratio, 1.49; 95% confidence interval, 0.63-3.50). Contrariwise, compared to inactivity, moderate physical activity (1.0-2.9 hours/week) was associated with a border-line significant decreased risk of venous thromboembolism among subjects under 60 years old (multivariable hazard ratio, 0.72; 95% confidence interval, 0.48-1.08) and subjects with a body mass index of less than 25 kg/m 2 (multivariable hazard ratio, 0.59; 95% confidence interval, 0.35-1.01). ConclusionsOur study showed that regular, moderate intensity physical exercise did not have a significant impact on the risk of venous thromboembolism in a general population. Future studies are required to assess the impact of regular physical exercise on venous thromboembolism risk in different population subgroups.Key words: venous thromboembolism, physical exercise, general population.Citation: Borch KH, Hansen-Krone I, Braekkan SK, Mathiesen EB, Njolstad I, Wilsgaard T, and Hansen J-B. Physical activity and risk of venous thromboembolism. The Tromsø study. Haematologica 2010;95(12):2088-2094. doi:10.3324/haematol.2009 © F e r r a t a S t o r t i F o u n d a t i o n

show abstract

“…15 The study was performed as a double-blind, placebocontrolled crossover trial. The study included three intervention periods of 6 weeks each interrupted by washout periods of 6 through 8 weeks.…”

Section: Experimental Designmentioning

confidence: 99%

Tissue-factor pathway inhibitor and lipoproteins. Evidence for association with and regulation by LDL in human plasma.

Hansen

Huseby

Sandset

et al. 1994

Arterioscler Thromb

Self Cite

View full text Add to dashboard Cite

Tissue-factor pathway inhibitor (TFPI) is a potent inhibitor of extrinsic coagulation, which is mainly associated with lipoproteins in circulating blood. Gel filtration of human plasma confirmed the presence of three peaks in which approximately 10%, 70%, and 20% of total TFPI activity was retained. Precipitation of very-low-density lipoproteins and low-density lipoproteins (LDLs) in plasma by polyethylene glycol almost completely abolished peaks I and II. LDL isolated by ultracentrifugation revealed two peaks of TFPI after gel filtration that coeluted with peaks I and II, respectively, from gel filtration of total plasma. TFPI activity in peaks I and II was also precipitated by anti-apolipoprotein B antibodies. Fourteen patients with familial hypercholesterolemia had higher plasma TFPI activity than did age-and sexmatched normolipemic control subjects (1.45±0.27 U/mL versus 0.80±0.09 U/mL, i><.001). Plasma TFPI was correlated with LDL cholesterol (r=.73, Z'<.001) and apolipoprotein B (r=.69, P<.001). No association was found with high-density lipoprotein cholesterol or apolipoprotein A-I. In a doubleblind, placebo-controlled trial among the familial hypercholesterolemia patients, lovastatin alone or in combination with fish oil concentrate lowered plasma TFPI in parallel with LDL cholesterol. Gel filtration of plasma from these patients demonstrated a specific drop in apolipoprotein B-TFPI complexes, whereas TFPI not associated with lipoproteins was unchanged. This study demonstrated that plasma TFPI was associated with and regulated by LDL in plasma from healthy subjects and patients with familial hypercholesterolemia. (Arterioscler Thromb. 1994;14:223-229.) Key Words • lovastatin • HMG-CoA reductase inhibitors • familial hypercholesterolemia • tissue-factor pathway inhibitor • lipoproteins I ncreasing evidence suggests that tissue factor (TF) provides the initial trigger for blood coagulation in normal hemostasis 1 and most likely plays a major role in thrombogenesis associated with atherosclerosis. Tissue-factor pathway inhibitor (TFPI) is a protease inhibitor that may function as a natural anticoagulant regulating TF-induced coagulation.3 TFPI needs factor Xa for its action and exerts its function by neutralizing factor Xa catalytic activity and by inactivating factor VIIa-TF catalytic activity. - 5TFPI has been established as the major plasma inhibitor of the factor VIIa-TF activity formed either in vitro with TF in suspension 6 or with TF expressed on the surface membrane of perturbed endothelial cells. 7 ' 8 In vivo studies in the rabbit also indicate that TFPI functions as a natural anticoagulant by inhibiting the factor VIIa-TF catalytic activity formed in circulating blood exposed to a iow concentration of TF. 9 Recently, Almus et al 10 have shown that moderate variation in plasma TFPI activity affects the ability of TFPI to inhibit factor VIIa-TF activity during hemostasis in an umbilical vein model. Received April 28, 1993; revision accepted October 25, 1993. Studies of normal individual...

show abstract

Inhibition of exercise-induced shortening of bleeding time by fish oil in familial hypercholesterolemia (type IIa).

Cited by 23 publications

References 36 publications

Effects of Simvastatin and omega‐3 fatty acids on plasma lipoproteins and lipid peroxidation in patients with combined hyperlipidaemia

Effects of Simvastatin and omega‐3 fatty acids on plasma lipoproteins and lipid peroxidation in patients with combined hyperlipidaemia

Physical activity and risk of venous thromboembolism. The Tromso study

Tissue-factor pathway inhibitor and lipoproteins. Evidence for association with and regulation by LDL in human plasma.

Contact Info

Product

Resources

About